Ascentis Independent Advisors
Position in LCTX — Lineage Cell Therapeutics, Inc.
CIK 1845003
DALLAS, TX
Position in LCTX
as of Mar 31, 2026
· filed Apr 28, 2026
Position Value
$48,840
New position
Shares Held
30,912
first reported quarter
Ownership
0.012%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Ascentis Independent Advisors holds $2,720,776 across 46 Biotechnology names. LCTX ranks #6 (1.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MIRM |
Mirum Pharmaceuticals, Inc.
|
19,380 | $1,790,324 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
476 | $367,774 | |
| 3 | INSM |
INSMED Inc
|
743 | $121,494 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
161 | $71,890 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
194 | $64,187 | |
| 6 | LCTX |
Lineage Cell Therapeutics, Inc.
This page
|
30,912 | $48,840 | |
| 7 | SGMOQ |
Sangamo Therapeutics, Inc
|
180,500 | $45,125 | |
| 8 | CRDF |
Cardiff Oncology, Inc.
|
24,500 | $39,690 |
All Filings in LCTX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $48,840 | 30,912 | Shares | Sole | 2026-04-28 | |
| No filing history on record for this holder in this stock. | ||||||